The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL.
Jacqueline Claudia Barrientos
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences
Richard R. Furman
Research Funding - Gilead Sciences
John Leonard
Consultant or Advisory Role - Gilead Sciences
Ian Flinn
Research Funding - Gilead Sciences
Kanti Roop Rai
Research Funding - Gilead Sciences
Sven De Vos
Research Funding - Gilead Sciences
Marshall T. Schreeder
Research Funding - Gilead Sciences
Nina D. Wagner-Johnston
No relevant relationships to disclose
Jeff Porter Sharman
Research Funding - Gilead Sciences
Thomas E. Boyd
Research Funding - Gilead Sciences
Nathan Hale Fowler
Research Funding - Gilead Sciences
Leanne Holes
Employment or Leadership Position - Gilead Sciences
David Michael Johnson
Employment or Leadership Position - Gilead Sciences
Daniel Li
Employment or Leadership Position - Gilead Sciences
Roger D. Dansey
Employment or Leadership Position - Gilead Sciences
Thomas Michael Jahn
Employment or Leadership Position - Gilead Sciences
Steven E. Coutre
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences